Maven Securities LTD Boosts Stock Position in Celgene Co. (NASDAQ:CELG)

Maven Securities LTD lifted its stake in Celgene Co. (NASDAQ:CELG) by 685.4% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 31,417 shares of the biopharmaceutical company’s stock after acquiring an additional 27,417 shares during the period. Celgene makes up about 1.9% of Maven Securities LTD’s holdings, making the stock its 18th largest holding. Maven Securities LTD’s holdings in Celgene were worth $2,897,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in CELG. Berman Capital Advisors LLC boosted its stake in shares of Celgene by 11.3% during the second quarter. Berman Capital Advisors LLC now owns 1,096 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 111 shares during the period. Bbva USA Bancshares Inc. raised its holdings in Celgene by 0.8% during the 2nd quarter. Bbva USA Bancshares Inc. now owns 13,271 shares of the biopharmaceutical company’s stock valued at $1,227,000 after buying an additional 111 shares during the last quarter. Global Retirement Partners LLC boosted its position in Celgene by 10.0% during the 1st quarter. Global Retirement Partners LLC now owns 1,269 shares of the biopharmaceutical company’s stock valued at $120,000 after buying an additional 115 shares during the period. MBM Wealth Consultants LLC boosted its position in Celgene by 2.8% during the 2nd quarter. MBM Wealth Consultants LLC now owns 4,264 shares of the biopharmaceutical company’s stock valued at $397,000 after buying an additional 116 shares during the period. Finally, Manchester Capital Management LLC boosted its position in Celgene by 1.2% during the 1st quarter. Manchester Capital Management LLC now owns 9,768 shares of the biopharmaceutical company’s stock valued at $922,000 after buying an additional 120 shares during the period. Institutional investors own 72.51% of the company’s stock.

Shares of CELG stock traded up $0.69 during mid-day trading on Wednesday, reaching $98.34. 265,008 shares of the company’s stock traded hands, compared to its average volume of 2,991,092. Celgene Co. has a 12 month low of $58.59 and a 12 month high of $98.97. The firm has a 50 day moving average price of $94.75 and a two-hundred day moving average price of $93.33. The firm has a market capitalization of $68.80 billion, a PE ratio of 12.93, a price-to-earnings-growth ratio of 0.45 and a beta of 1.41. The company has a debt-to-equity ratio of 1.97, a quick ratio of 3.32 and a current ratio of 3.44.

Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $2.61 EPS for the quarter, topping analysts’ consensus estimates of $2.44 by $0.17. Celgene had a return on equity of 89.93% and a net margin of 32.24%. The business had revenue of $4.40 billion during the quarter, compared to analysts’ expectations of $4.22 billion. During the same quarter in the prior year, the business posted $2.16 earnings per share. The business’s quarterly revenue was up 15.4% on a year-over-year basis. As a group, equities analysts expect that Celgene Co. will post 9.96 earnings per share for the current fiscal year.

A number of research firms have commented on CELG. Mizuho lowered Celgene from a “buy” rating to a “neutral” rating and lowered their price target for the company from $103.00 to $100.00 in a research report on Monday, August 19th. Zacks Investment Research raised shares of Celgene from a “sell” rating to a “hold” rating and set a $94.00 target price for the company in a research report on Tuesday, July 23rd. Cowen reiterated a “hold” rating and set a $102.00 target price on shares of Celgene in a report on Tuesday, July 30th. ValuEngine cut shares of Celgene from a “sell” rating to a “strong sell” rating in a report on Thursday, August 1st. Finally, BidaskClub cut Celgene from a “buy” rating to a “hold” rating in a research report on Saturday. One equities research analyst has rated the stock with a sell rating, eighteen have issued a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average price target of $94.60.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: What causes a stock to be most active?

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.